Evidence for extensive pleiotropy among pharmacogenes

  • Matthew T. Oetjens
  • , William S. Bush
  • , Joshua C. Denny
  • , Kelly Birdwell
  • , Nuri Kodaman
  • , Anurag Verma
  • , Holli H. DIlks
  • , Sarah A. Pendergrass
  • , Marylyn D. Ritchie
  • , Dana C. Crawford

Research output: Contribution to journalArticlepeer-review

Abstract

Aim: We sought to identify potential pleiotropy involving pharmacogenes. Methods: We tested 184 functional variants in 34 pharmacogenes for associations using a custom grouping of International Classification and Disease, Ninth Revision billing codes extracted from deidentified electronic health records of 6892 patients. Results: We replicated several associations including ABCG2 (rs2231142) and gout (p = 1.73 × 10-7; odds ratio [OR]: 1.73; 95% CI: 1.40-2.12); and SLCO1B1 (rs4149056) and jaundice (p = 2.50 × 10-4; OR: 1.67; 95% CI: 1.27-2.20). Conclusion: In this systematic screen for phenotypic associations with functional variants, several novel genotype-phenotype combinations also achieved phenome-wide significance, including SLC15A2 rs1143672 and renal osteodystrophy (p = 2.67 × 10- 6; OR: 0.61; 95% CI: 0.49-0.75).

Original languageEnglish (US)
Pages (from-to)853-866
Number of pages14
JournalPharmacogenomics
Volume17
Issue number8
DOIs
StatePublished - Jun 2016

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Genetics
  • Pharmacology

Fingerprint

Dive into the research topics of 'Evidence for extensive pleiotropy among pharmacogenes'. Together they form a unique fingerprint.

Cite this